Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) has received a consensus rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $2.50.
A number of brokerages have commented on HOWL. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 3rd.
View Our Latest Report on HOWL
Institutional Investors Weigh In On Werewolf Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC raised its stake in shares of Werewolf Therapeutics by 99.6% in the third quarter. Virtu Financial LLC now owns 90,749 shares of the company’s stock valued at $84,000 after acquiring an additional 45,282 shares in the last quarter. StoneX Group Inc. grew its stake in Werewolf Therapeutics by 174.3% during the 3rd quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock worth $51,000 after buying an additional 34,856 shares during the last quarter. Covestor Ltd acquired a new stake in shares of Werewolf Therapeutics in the third quarter valued at approximately $124,000. Vontobel Holding Ltd. acquired a new stake in Werewolf Therapeutics during the 3rd quarter worth $55,000. Finally, Vilga Financial Planning LLC acquired a new stake in Werewolf Therapeutics during the 3rd quarter worth $49,000. 64.84% of the stock is owned by hedge funds and other institutional investors.
Werewolf Therapeutics Trading Down 1.9%
Shares of HOWL stock opened at $1.03 on Thursday. Werewolf Therapeutics has a 12-month low of $0.27 and a 12-month high of $1.20. The stock’s 50-day moving average price is $0.99 and its 200-day moving average price is $0.71. The stock has a market capitalization of $50.06 million, a price-to-earnings ratio of -1.72 and a beta of 0.55.
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.02. As a group, research analysts predict that Werewolf Therapeutics will post -0.89 EPS for the current fiscal year.
Werewolf Therapeutics Company Profile
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body’s immune response against tumors. The company’s INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.
See Also
- Five stocks we like better than Werewolf Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
